Drugs that contain Nilotinib Hydrochloride

1. Drug name - TASIGNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169791 NOVARTIS Inhibitors of tyrosine kinases
Jul, 2023

(8 months from now)

US8415363 NOVARTIS Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jul, 2026

(3 years from now)

US8163904 NOVARTIS Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
Aug, 2028

(5 years from now)

US9061029 NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Apr, 2032

(9 years from now)

CN102358736A NOVARTIS 4-Methyl-N - [4 - (3-Methyl-Imidazole - -1 - Yl)--5 - Trifluoromethyl-Phenyl] -3-(4-Pyridine - -3 - Yl-Pyrimidine - -2 - Ylamino) - Form Benzamide
Mar, 2015

(7 years ago)

CN102267981A NOVARTIS Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidine-2-Ylamino)-Benzamide
Jun, 2015

(7 years ago)

CN103804356A NOVARTIS 4-Methyl-N-[3-(4-Methyl-Imidazol--1-Base)--5-Trifluoromethyl-Phenyl]--3-(4-Pyridin--3-Base-Pyrimidin--2-Ylamino)-Benzamide Of Crystalline Form
Mar, 2016

(6 years ago)

CN1675195A NOVARTIS Tyrosine Kinase Inhibitors
Jul, 2023

(8 months from now)

CN1324022C NOVARTIS Tyrosine Kinase Inhibitors
Jul, 2023

(8 months from now)

CN101228151B NOVARTIS Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidine-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

CN101228150B NOVARTIS 4-Methyl-N - [4 - (3-Methyl-Imidazole - -1 - Yl)--5 - Trifluoromethyl-Phenyl] -3-(4-Pyridine - -3 - Yl-Pyrimidine - -2 - Ylamino) - Form Benzamide
Jul, 2026

(3 years from now)

CN101228150A NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

CN101228151A NOVARTIS Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Base-Pyrimidin-2-Yl-Amino)-Benzamide
Jul, 2026

(3 years from now)

CN102612368A NOVARTIS Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity
Nov, 2030

(8 years from now)

CN102612368B NOVARTIS Method Of Treating Proliferation Disorders And Other Pathological Conditions Mediated By Bar-Abl, C-Kit, Ddr1 Or Pdgf-R Kinase Activity
Nov, 2030

(8 years from now)

IN237430B NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

IN200403003P4 NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

EP1532138B1 NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

EP2357182A1 NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

EP2357182B1 NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

EP1532138A1 NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

EP2535337B1 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide Sulfate And Its Amorphous Form
Jul, 2026

(3 years from now)

EP2535337A1 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide Sulfate And Its Amorphous Form
Jul, 2026

(3 years from now)

EP1912973B1 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2284167A2 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2186808A1 NOVARTIS Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP1910336B1 NOVARTIS Monohydrochloride Monohydrate Salt Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2284167B2 NOVARTIS Crystalline Form Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2284167B1 NOVARTIS Crystalline Form Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP1910336A1 NOVARTIS Monohydrochloride Monohydrate Salt Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2186808B1 NOVARTIS Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP1912973A2 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2284167A3 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2501384B1 NOVARTIS Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity
Nov, 2030

(8 years from now)

EP2501384A1 NOVARTIS Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity
Nov, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169791

(Pediatric)

NOVARTIS Inhibitors of tyrosine kinases Jan, 2024

(1 year, 2 months from now)

US8501760 NOVARTIS Pharmaceutical compositions comprising nilotinib or its salt Jul, 2026

(3 years from now)

US8389537 NOVARTIS Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide Jul, 2026

(3 years from now)

US8415363

(Pediatric)

NOVARTIS Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide Jan, 2027

(4 years from now)

US8501760

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising nilotinib or its salt Jan, 2027

(4 years from now)

US8389537

(Pediatric)

NOVARTIS Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide Jan, 2027

(4 years from now)

US8293756 NOVARTIS Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate Sep, 2027

(4 years from now)

US8293756

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate Mar, 2028

(5 years from now)

US8163904

(Pediatric)

NOVARTIS Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide Feb, 2029

(6 years from now)

US9061029

(Pediatric)

NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity Oct, 2032

(10 years from now)

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription
EQ 200MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.